Intervention: Ixazomib
Trial phase: Phase 1
ATC code: L01XG03
SMILES: CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Ixazomib (MLN9708) 2.34 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
Eligibility criteria:
Inclusion Criteria:

Each participant must meet all of the following inclusion criteria to be enrolled in the study:

Male or female participants 18 years or older.
Eastern Cooperative Oncology Group performance status 0-2.
A diagnosis of a nonhematologic malignancy for which standard treatment is no longer effective. In the expanded cohort, enrollment will be limited to participants with a diagnosis of NSCLC, H&N cancer (squamous cell cancer), STS, or PC.
Suitable venous access for pharmacokinetic (PK) and pharmacodynamic evaluations.

Female participants who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or abstain from heterosexual intercourse.

Male participants who agree to practice 2 effective methods of contraception or abstain from heterosexual intercourse.

Voluntary written consent must be obtained.
Adequate clinical laboratory values during the screening period.
In the escalation portion of the study, radiographically or clinically evaluable tumor was required, but measurable disease as defined by response evaluation criteria in solid tumors (RECIST) criteria was not required. In the MTD disease expansion cohorts and the TPEC, clinically measurable disease as defined by RECIST criteria was required for evaluation of NSCLC, H&N cancer, and STS. Prostate specific antigen (PSA) alone was acceptable for evaluation of PC.
For participants in the TPEC, tumor tissue that, in the opinion of the investigator, could have been safely biopsied using a core needle.

Exclusion Criteria:

Participants meeting any of the following exclusion criteria are not to be enrolled in the study:

Peripheral neuropathy greater than or equal to (>=) Grade 2.
Female participants who are lactating or have a positive serum pregnancy test during the screening period.
Major surgery within 14 days before the first dose of treatment.
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before the first dose of study treatment.
Life-threatening illness unrelated to cancer.
Diarrhea greater than (>) Grade 1 based on the National Cancer Institute Common Terminology .Criteria for Adverse Events (NCI CTCAE) categorization.
Systemic antineoplastic therapy / or radiotherapy within 21 days before the first dose of study treatment.
Systemic treatment with prohibited medications.
Participant has symptomatic brain metastasis.
Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure (CHF), angina, or myocardial infarction within the past 6 months.
QTc >470 milliseconds (msec) on a 12-lead electrocardiogram (ECG) obtained during the screening period.
Known human immunodeficiency virus (HIV), hepatitis B or hepatitis C positive.
Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
Treatment with any investigational products within 28 days before the first dose of study treatment.
For participants in the TPEC and participants in the MTD disease expansion cohorts who gave informed consent to undergo tumor biopsy, ongoing anticoagulant therapy (example, aspirin, clopidogrel [Plavix ®], warfarin, or heparin) that cannot be held to permit tumor biopsy .
Known allergy to boron or excipients.